Vivo Capital LLC bought a new position in shares of Q32 Bio Inc. (NASDAQ:QTTB - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 370,068 shares of the company's stock, valued at approximately $6,306,000. Vivo Capital LLC owned about 11.37% of Q32 Bio at the end of the most recent reporting period.
Q32 Bio Price Performance
Shares of NASDAQ QTTB traded down $0.22 during midday trading on Friday, reaching $28.02. 28,395 shares of the stock were exchanged, compared to its average volume of 49,991. Q32 Bio Inc. has a twelve month low of $8.24 and a twelve month high of $30.92. The company has a market capitalization of $91.35 million, a P/E ratio of -0.79 and a beta of -0.10.
Q32 Bio (NASDAQ:QTTB - Get Free Report) last posted its earnings results on Tuesday, March 12th. The company reported ($4.32) EPS for the quarter. As a group, research analysts expect that Q32 Bio Inc. will post -4.37 EPS for the current year.
Wall Street Analyst Weigh In
A number of brokerages recently commented on QTTB. Oppenheimer started coverage on Q32 Bio in a research report on Thursday, April 11th. They set an "outperform" rating and a $50.00 price objective on the stock. Piper Sandler began coverage on shares of Q32 Bio in a research report on Tuesday, April 2nd. They set an "overweight" rating and a $45.00 price target on the stock.
Read Our Latest Research Report on QTTB
About Q32 Bio
(
Free Report)
Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics targeting powerful regulators of the innate and adaptive immune systems to rebalance immunity in autoimmune and inflammatory diseases. Its products in the pipeline include ADX-914, a human anti-IL-7R antibody that re-regulates adaptive immune function, and ADX-097, which has in vivo biodistribution to affected tissues and organs, durable tissue pharmacokinetics and pharmacodynamics, and robust in vivo efficacy.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Q32 Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Q32 Bio wasn't on the list.
While Q32 Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
